NASDAQ:CRSP

CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

CRISPR Therapeutics logo
$40.19 +0.04 (+0.10%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$40.84 +0.65 (+1.60%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CRISPR Therapeutics Stock (NASDAQ:CRSP)

Advanced

Key Stats

Today's Range
$40.10
▼
$42.66
50-Day Range
$40.15
▼
$59.03
52-Week Range
$39.79
▼
$63.45
Volume
3.98 million shs
Average Volume
1.78 million shs
Market Capitalization
$3.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.93
Consensus Rating
Moderate Buy

Company Overview

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts.

Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval. The companies share responsibilities for developing and commercializing Casgevy in authorized markets.

Beyond Casgevy, CRISPR Therapeutics is advancing research programs in areas including cancer, autoimmune disease and in vivo gene editing. The company is led by CEO Samarth Kulkarni.

AI Generated. May Contain Errors.

CRISPR Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

CRSP MarketRank™: 
2.90627569197 of 5 stars

CRISPR Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 765th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 2 strong buy ratings, 8 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside Potential

    CRISPR Therapeutics has a consensus price target of $72.93, representing about 81.5% upside from its current price of $40.19.

  • Amount of Analyst Coverage

    CRISPR Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CRISPR Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($4.54) to ($3.84) per share.

  • Price to Book Value per Share Ratio

    CRISPR Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.69% of the float of CRISPR Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CRISPR Therapeutics has a short interest ratio ("days to cover") of 13.09, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CRISPR Therapeutics has recently increased by 4.54%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CRISPR Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CRISPR Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    CRISPR Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for CRISPR Therapeutics this week, compared to 10 articles on an average week.
  • Search Interest

    20 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,881,663.00 in company stock.

  • Percentage Held by Insiders

    5.20% of the stock of CRISPR Therapeutics is held by insiders.

  • Percentage Held by Institutions

    69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about CRISPR Therapeutics' insider trading history.
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRSP Stock News Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Headlines

CRSP Stock Analysis - Frequently Asked Questions

CRISPR Therapeutics' stock was trading at $52.44 on January 1st, 2026. Since then, CRSP shares have decreased by 23.4% and is now trading at $40.19.

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Monday, November, 2nd. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.06) by $0.09. The business's revenue for the quarter was up 1311.1% compared to the same quarter last year.

CRISPR Therapeutics (CRSP) raised $64 million in an IPO on Wednesday, October 19th 2016. The company issued 4,000,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Top institutional shareholders of CRISPR Therapeutics include State Street Corp (5.15%), GSK plc (2.69%), Sumitomo Mitsui Trust Group Inc. (1.50%) and Goldman Sachs Group Inc. (0.24%). Insiders that own company stock include Samarth Kulkarni, James R Kasinger, Naimish Patel, Ali Behbahani, Simeon George, Julianne Bruno, John Greene and Raju Prasad.
View institutional ownership trends
.

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Micron Technology (MU), Editas Medicine (EDIT) and Block (XYZ).

Company Calendar

Last Earnings
11/02/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRSP
CIK
1674416
Fax
N/A
Employees
393
Year Founded
2013

Price Target and Rating

High Price Target
$110.00
Low Price Target
$45.00
Potential Upside/Downside
+81.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$581.60 million
Net Margins
-1,812.07%
Pretax Margin
-1,802.19%
Return on Equity
-25.59%
Return on Assets
-17.89%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
16.21
Quick Ratio
16.21

Sales & Book Value

Annual Sales
$3.51 million
Price / Sales
1,110.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.99 per share
Price / Book
2.37

Miscellaneous

Outstanding Shares
97,000,000
Free Float
91,957,000
Market Cap
$3.90 billion
Optionable
Optionable
Beta
1.92

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:CRSP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners